



NEPTUNE
technologies & bioresources

500 St-Martin Blvd. West
Suite 550
Laval (Québec)
Canada H7M 3Y2

Telephone: (450) 972-6291
Toll free: 1 888 664-9166
Fax: (450) 972-6351
www.neptunebiotech.com

Ms. Gloria Chang
Acting Team Leader
Dietary Supplement Team
Division of Standards and Labeling
HFS-821,
CFSAN, FDA
200 C Street, SW
Washington, DC 20204
Telephone No. 301-436-1853

April 26, 2002


Re: ITPN 79419
Dear Ms. Chang,

Please find enclosed the supplementary information requested.

Please contact me if further information is required at:
tel.: 450-972-6291
cell: 514-865-9917
e-mail: tinas@neptunebiotech.com

Best Regards

Tina Sampalis M.D., Ph.D.
Vice President Research



nc

APPENDIX A : Photostatic copies or reprints of the full-published references,

APPENDIX B : Neptune Krill Oil TM serving and daily dose

APPENDIX C : Neptune Aquateine TM serving and daily dose

APPENDIX D : LyO-Krill daily serving and dose

APPENDIX E : Neptune Krill Enzymes TM serving and daily dose

APPENDIX F : Scientific Report

APPENDIX G : processing techniques used

APPENDIX H : Krill additive by Nippon Suisan

**Neptune Technologies & Bioresources Inc.
Information Package**

Table of Contents

1. General information requested
2. Appendix A : Photostatic copies or reprints of the full-published references, citations, and articles in English:
 - a. Krill
 - b. Cardiovascular disease
 - c. Inflammatory disease
 - d. Phospholipids
 - e. Astaxanthin
3. Appendix B : Neptune Krill Oil™ serving and daily dose
4. Appendix C : Neptune Aquateine™ serving and daily dose
5. Appendix D : LyO-Krill daily serving and dose
6. Appendix E: Neptune Krill Enzymes™ serving and daily dose
7. Appendix F: Scientific Report
8. Appendix G: processing techniques used:
 - a. Neptune Krill Oil™ & Neptune Aquateine™
 - b. LyO-Krill
9. Appendix H: Krill additive by Nippon Suisan

SUPPLEMENTARY INFORMATION

- The references included abstracts. I informed her that we needed photostatic copies or reprints of the full-published references, citations, and articles in English.
 - Please refer to “Appendix A”

- The specific species of Krill was not identified in the notification. I ask if there was a specific species that was to be marketed. Dr. Sampalis stated that there was, and that she would provide that information to us.
 - The krill species used is: Antarctic Krill *Euphasia superba* fished in the Antarctic ocean near the South Georgia and Sandwich Islands

- The notification was unclear as to what form of the Krill was to be orally ingested, there were 3 forms: the oil extract, the dry fraction, and the freeze-dried form. Dr. Sampalis stated that all three forms were to be marketed for oral ingestion. I asked her to indicate this in her response.
 - All three forms are meant for oral ingestion:
 - Neptune Krill Oil™ : gel caps (1 gram of oil per gel cap)
 - Aquateine™ (dry fraction): powder
 - LyO-Krill (freeze dried): capsules (300mg per capsule)

- **The notification was unclear as to the specific levels or concentration of Krill per serving dose for each form (i.e., the oil extract, the dry fraction, and the freeze-dried Krill) and the total daily serving intake and I asked Dr. Sampalis to provide information for all three forms. I also requested if there was any limitation or duration of use and frequency of serving doses (e.g., how many times a day it is taken), if so, to please indicate, if not to also state this.**
 - Neptune Krill Oil™ : gel caps
 - 1 gram of oil per gel cap
 - recommended dose = 1 – 3 gel caps per day
 - Daily dose: Appendix B

 - Aquateine™ (dry fraction): powder
 - 300mg per sac
 - recommended dose = 1 – 3 sacs per day
 - Daily dose: Appendix C

 - LyO-Krill (freeze dried): capsules
 - 300mg per capsule
 - recommended dose = 1 – 3 capsules per day
 - Daily dose: Appendix D

 - Limitations:
 - No limitation in the duration of use

- **Because the target population was not clear or missing, to provide the target population that the NDI would be used. If there is no target population, to please indicate that. To also provide information if there is any excluded populations such as pregnant/lactating women, the elderly, children or infants (state age range if any) or other populations with specific disease or medical conditions. If so, to specify, if not also state this.**
 - There is no target population
 - Excluded populations:
 - Seafood allergy
 - Anticoagulant use

- **I also asked Dr. Sampalis to submit the requested complete information in triplicate.**
 - Three copies enclosed

- **Also please make sure that the complete processing information for all three forms, if not in original submission notification, are included in the submission, (i.e., the processing technique used, the chemicals, compounds, or other ingredients used in processing if any, the drying and freezing techniques, etc.)**
 - Please refer to “Appendix E”

- **If there are any other ingredients in the various serving (dosage) forms such as excipients, flavors, coloring, preservatives, stabilizers, etc, also please identify and indicate levels.**
 - The company that fishes the raw material (krill) in the Antarctic add “sodium hydrogen sulfite (NaHSO₃)” as an additive upon freezing. The amount of NaHSO₃ in krill is approximately 100 ppm.
 - There are no other ingredients included in any of the serving forms